Tumor dormancy therapy in head and neck cancer

Abstract

For the purpose of tumor dormancy therapy, UFT+Mitomycin C or TS-1 in patients with recurrent head and neck cancer was studied. Toxicity was not greater in the patients with a higher incidence of grade 2. One patient has survived for more than 4 years, having been given UFT+Mitomycin C at the beginning. For patients with lung metastasis, median survival time was 600 days, and time to progression was 4.5 months in the TS-1 group (n=4). TS-1 method was useful in terms of QOL. Based on these results, we believe that tumor dormancy therapy will be realized for the treatment of recurrent or lung metastastic head and neck cancer.